GlaxoSmithKline and Endo Pharmaceuticals have agreed to settle lawsuits that accused both companies of obscuring the risks of a testosterone-boosting drug marketed to middle-aged men, according to court filings.
The settlement is set to resolve more than 1,300 suits filed by men who blame the Endo-manufactured drug, which was promoted by GSK, for causing blood clots.
U.S. District Judge Matthew Kennelly, who is overseeing more than 6,000 testosterone cases, is putting on hold all litigation against Endo and GSK while the the settlement details are finalized.
Read the Bloomberg Report